← Back to Search

A Sleep Intervention in Type 1 Diabetes

Chicago, IL
N/A
Waitlist Available
Led By Pamela Martyn-Nemeth, PhD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change between two time points, week 0 to week 8
Awards & highlights
No Placebo-Only Group

Summary

Insufficient sleep and sleep irregularity (variability in sleep duration) are increasingly recognized as important contributors to glucose control and diabetes distress in type 1 diabetes (T1D). Up to 40% of adults with T1D had a sleep duration less than 6-6.5 hours per night. Diabetes distress is reported (40% prevalence) in individuals with T1D and is associated with poor glucose control. Despite findings that sleep disturbances are common in T1D, the current understanding of the effects of strategies to improve sleep on diabetes distress, and glucose control is limited. The purpose of this pilot study is to evaluate the effects of a sleep intervention on sleep duration, diabetes distress and glucose control in individuals with T1D and habitual short sleep. A randomized controlled trial in 20 adults aged 18 to 65 years with T1D is proposed. Eligible participants will be randomly assigned to a sleep intervention group or a control group. Differences between the two groups on the outcomes of sleep duration, diabetes distress and glucose control will be evaluated. Findings from this proposed pilot study will serve as the foundation for a larger clinical trial to improve sleep, reduce diabetes distress, and improve glucose control.

See full description
Eligible Conditions
  • Insomnia
  • Type 1 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change between two time points, week 0 to week 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and change between two time points, week 0 to week 8 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sleep Duration
Sleep Regularity
Secondary study objectives
Diabetes Distress
Glucose Variability
HbA1c

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Sleep-Opt-InExperimental Treatment1 Intervention
Sleep optimization intervention
Group II: Healthy LivingActive Control1 Intervention
Health education
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sleep Opt-In
2019
N/A
~20

Find a Location

Closest Location:University of Illinois at Chicago· Chicago, IL

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor
647 Previous Clinical Trials
1,571,009 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,492 Previous Clinical Trials
4,358,706 Total Patients Enrolled
University of ChicagoOTHER
1,077 Previous Clinical Trials
841,820 Total Patients Enrolled
Pamela Martyn-Nemeth, PhDPrincipal InvestigatorUniversity of Illinois at Chicago
3 Previous Clinical Trials
205 Total Patients Enrolled
~2 spots leftby Feb 2026